3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
1
Melanoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
218
Fluorouracil
142
Oxaliplatin
132
Capecitabine
122
pembrolizumab
113
Irinotecan
110
Leucovorin
104
Bevacizumab
98
Nivolumab
80
Cisplatin
80
130-nm albumin-bound paclitaxel
80
Cetuximab
79
Radiotherapy
78
Albumin-Bound Paclitaxel
59
Sorafenib
56
Paclitaxel
53
Cyclophosphamide
50
Carboplatin
47
Magnetic Resonance Spectroscopy
44
Specimen Handling
39
Docetaxel
37
Taxes
36
fludarabine
34
Radiation
34
durvalumab
33
Ipilimumab
33
Erlotinib Hydrochloride
33
Biopsy
33
Radiosurgery
27
Folfox protocol
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
LY3300054
×
Gastrointestinal
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled